Breaking News Instant updates and real-time market news.

NKTR

Nektar

$34.06

-1.24 (-3.51%)

08:55
11/10/18
11/10
08:55
11/10/18
08:55

Nektar to hold a conference call

Dr. Harriet Kluger of Yale Cancer Center and Dr. Diab of Anderson Cancer Center discuss their presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting on a conference call to be held on November 10 at 9 am. Webcast Link

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 27

    Nov

NKTR Nektar
$34.06

-1.24 (-3.51%)

11/08/18
HCWC
11/08/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar shares may have bottomed, says H.C. Wainwright
During last night's Q3 corporate update call, Nektar Therapeutics provided clarity on soon to be initiated Phase 3 programs, with a vital expansion cohort in second line non-small cell lung cancer, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. While the renal cell carcinoma, bladder, and melanoma studies were telegraphed previously, "clarity was welcome news for the bulls," says Chattopadhyay. However, the analyst adds that RCC and melanoma remain very crowded and that the initiation of triplet studies, if successfully clinically, "would significantly add to the financial toxicity discussion, especially since NKTR-214 is likely to be marketed as a unique medicine." Chattopadhyay thinks the newly defined cohort of approximately 100 second-line NSCLC patients to the ongoing Pivot trial is key to sentiment around the NKTR-214 story during the second half of 2019. He attributes the recent pullback in Nektar shares to disappointment from the preliminary read from the SITC abstract. Nonetheless, with a host of trial initiations and multiple combination updates at disease specific conferences during 2019, the stock may have bottomed, Chattopadhyay writes. However, the analyst says that while the study initiations and data releases should "quell some fears," the data quality "needs a pickup." He keeps a Neutral rating on Nektar with a $47 price target.
11/08/18
JEFF
11/08/18
NO CHANGE
Target $73
JEFF
Buy
Nektar price target lowered to $73 from $103 at Jefferies
Jefferies analyst David Steinberg lowered his price target for Nektar Therapeutics (NKTR) to $73 after reducing his assumptions for NKTR-214 to reflect a potentially prolonged delay in non-small-cell lung carcinoma. The analyst, however, keeps a Buy rating on the shares following the company's Q3 results. He points out that Nektar's partnership with Bristol-Myers (BMY) as well as its other collaborations are ramping up.
11/06/18
PIPR
11/06/18
NO CHANGE
PIPR
Nektar abstract references old 50% ORR, says Piper Jaffray
The regular Society for Immunotherapy of Cancer abstract that provides an update of the first line melanoma patient cohort in the ongoing PIVOT-02 trial testing the combination of Nektar Therapeutics's NKTR-214 plus Opdivo was posted, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. He points out that 41 patients were enrolled with 38 evaluable for efficacy and the investigator-assessed objective response rate as of July 12 was 50%. Van Buren says that while is this is what we already knew, it confirms his prior assumption of the 50% response rate floor heading into the Friday afternoon updated data presentation. On Friday, the analyst expects to receive an updated response rate and more details on the quality of response. Finally, no responder has relapsed in this cohort and median duration of response has not been reached, which is promising as we begin to think about the probability of success for the Phase III trial, says the analyst. Shares of Nektar are down 7%, or $2.75, to $37.25 in pre-market trading.
11/05/18
HCWC
11/05/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar price target lowered to $47 from $54 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Nektar Therapeuticsless than (NKTR) to $47 and keeps a Neutral rating on the shares. While the Phase 3 trial of Opdivo plus NKTR-214 is welcome news, the company faces a crowded frontline renal cell carcinoma treatment landscape and stiff commercial hurdles, Chattopadhyay tells investors in a research note. He believes that unless the NKTR-214 plus Opdivo combination is meaningfully superior to the Opdivo and Yervoy combination, Bristol-Myers (BMY) "may not be willing to muscle the commercial launch, given the cannibalization of its existing franchise."

TODAY'S FREE FLY STORIES

CTRP

Ctrip

$32.55

-1.24 (-3.67%)

14:35
02/21/19
02/21
14:35
02/21/19
14:35
Options
Ctrip.com put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 04

    Mar

  • 20

    Mar

NAII

Natural Alternatives International

$11.15

(0.00%)

14:34
02/21/19
02/21
14:34
02/21/19
14:34
Hot Stocks
Natural Alternatives International hires David Brook for sports nutrition unit »

Natural Alternatives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

14:24
02/21/19
02/21
14:24
02/21/19
14:24
Hot Stocks
Nintendo of America president, COO Reggie Fils-Aime to retire »

Nintendo announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.83

-0.21 (-1.40%)

14:23
02/21/19
02/21
14:23
02/21/19
14:23
Hot Stocks
Fiat Chrysler to propose EUR0.65 per share dividend »

Fiat Chrysler Automobiles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$43.43

-0.32 (-0.73%)

14:20
02/21/19
02/21
14:20
02/21/19
14:20
Options
20K iShares Brazil Fund Mar 44 - 46 call spreads sold at 60c »

20K iShares Brazil Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
02/21/19
02/21
14:17
02/21/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
02/21/19
02/21
14:16
02/21/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$34.55

-1.08 (-3.03%)

14:15
02/21/19
02/21
14:15
02/21/19
14:15
Options
Baozun put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THRM

Gentherm

$44.16

1.3 (3.03%)

14:11
02/21/19
02/21
14:11
02/21/19
14:11
Downgrade
Gentherm rating change  »

Craig-Hallum downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

PTC

PTC

$91.88

0.04 (0.04%)

14:08
02/21/19
02/21
14:08
02/21/19
14:08
Hot Stocks
New offering from PTC and ANSYS brings real-time simulation to design engineers »

PTC announced the release…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 14

    Mar

HSC

Harsco

$24.48

2.54 (11.58%)

14:06
02/21/19
02/21
14:06
02/21/19
14:06
Recommendations
Harsco analyst commentary  »

Harsco has opportunity to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

THRM

Gentherm

$44.10

1.24 (2.89%)

14:06
02/21/19
02/21
14:06
02/21/19
14:06
Downgrade
Gentherm rating change  »

Gentherm downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.66

-0.76 (-0.27%)

14:04
02/21/19
02/21
14:04
02/21/19
14:04
Periodicals
CEO of container ship giant Maersk sees global trade war escalation, FT says »

Moller-Maersk CEO Soren…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.66

-0.76 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSU

Tim Participacoes

$16.28

0.01 (0.06%)

13:58
02/21/19
02/21
13:58
02/21/19
13:58
Hot Stocks
Breaking Hot Stocks news story on Tim Participacoes »

TIM Participacoes trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$30.85

-0.01 (-0.03%)

13:55
02/21/19
02/21
13:55
02/21/19
13:55
Hot Stocks
AT&T sees discontinuing 3G service in early 2022 »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 11

    Mar

  • 11

    Mar

  • 20

    Mar

PXD

Pioneer Natural

$137.13

-4.15 (-2.94%)

13:55
02/21/19
02/21
13:55
02/21/19
13:55
Options
Pioneer Natural put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

INVE

Identiv

$5.77

0.02 (0.35%)

13:55
02/21/19
02/21
13:55
02/21/19
13:55
Conference/Events
Identiv to participate in a conference call with Northland »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GOOG

Alphabet

$1,100.85

-13.06 (-1.17%)

, GOOGL

Alphabet Class A

$1,106.69

-13.91 (-1.24%)

13:47
02/21/19
02/21
13:47
02/21/19
13:47
Periodicals
AT&T tells Bloomberg removing YouTube ads »

AT&T (T) said in an…

GOOG

Alphabet

$1,100.85

-13.06 (-1.17%)

GOOGL

Alphabet Class A

$1,106.69

-13.91 (-1.24%)

T

AT&T

$30.88

0.015 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

  • 11

    Mar

  • 11

    Mar

  • 18

    Mar

  • 20

    Mar

SPCB

SuperCom

$1.68

(0.00%)

13:43
02/21/19
02/21
13:43
02/21/19
13:43
Hot Stocks
SuperCom secures new electonic monitoring contract in Southern Georgia »

SuperCom announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

NSRGY

Nestle

$0.00

(0.00%)

, DIS

Disney

$114.00

0.305 (0.27%)

13:38
02/21/19
02/21
13:38
02/21/19
13:38
Periodicals
YouTube sends memo to address 'brand safety' controvery, AdWeek reports »

YouTube (GOOG, GOOGL)…

NSRGY

Nestle

$0.00

(0.00%)

DIS

Disney

$114.00

0.305 (0.27%)

GOOGL

Alphabet Class A

$1,108.85

-11.75 (-1.05%)

GOOG

Alphabet

$1,103.04

-10.87 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 03

    Mar

  • 07

    Mar

  • 18

    Mar

CF

CF Industries

$43.96

-0.58 (-1.30%)

13:35
02/21/19
02/21
13:35
02/21/19
13:35
Options
CF Industries put volume heavy and directionally bearish »

Bearish flow noted in CF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 28

    May

MLNT

Melinta Therapeutics

$1.30

-0.035 (-2.62%)

13:32
02/21/19
02/21
13:32
02/21/19
13:32
Hot Stocks
Melinta Therapeutics announces one-for-five reverse stock split »

Melinta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLO

Valero

$84.85

-0.51 (-0.60%)

13:27
02/21/19
02/21
13:27
02/21/19
13:27
Conference/Events
Valero management to meet with JPMorgan »

Meeting to be held Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

13:25
02/21/19
02/21
13:25
02/21/19
13:25
Conference/Events
The Federal Energy Regulatory Commission (FERC) to hold a meeting »

Open Commission Meeting…

MGM

MGM Resorts

$28.56

-0.26 (-0.90%)

13:24
02/21/19
02/21
13:24
02/21/19
13:24
Conference/Events
MGM Resorts management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.